Caredx reports preliminary revenue results for fourth quarter and full year 2023

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) – the transplant company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today reported preliminary financial results for the fourth quarter and full year ended december 31, 2023. fourth quarter and full year 2023 highlights full year 2023 revenue is expected to be in the range of $279 million to $280 million, which i.
CDNA Ratings Summary
CDNA Quant Ranking